세계의 응고제 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 투여 채널별, 지역별, 부문별 예측(2024-2030년)

Coagulants Market Size, Share & Trends Analysis Report By Product (Systemic, Topical, Hemostatics), By Application (Surgeries, Trauma, Hemophilia, Bleeding), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,163,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,536,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,280,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

응고제 시장 규모 및 동향

세계 응고제 시장 규모는 2023년 104억 7,000만 달러로 추정되며, 2024-2030년간 연평균 7.2% 성장할 것으로 예상됩니다. 의료 시장은 주로 치료에 혈액응고인자가 필요한 출혈성 질환과 만성 질환의 유병률 증가에 의해 주도되고 있습니다. 혈우병, 폰 빌레브란트병, 혈전증과 같은 질환은 응고인자를 사용하여 효과적으로 관리 및 통제해야 합니다. 전 세계적으로 이러한 질병의 발생률이 증가함에 따라 이 시장 수요가 증가하고 있습니다.

또한, 기술 발전과 새로운 응고 요법의 개발은 기술 혁신을 촉진하여 이 부문을 확장하고 있습니다. 제조업체들은 유전자 재조합 응고인자 제제, 반감기 연장 제제 등 보다 효과적이고 안전한 제품을 출시하기 위해 연구개발에 투자하고 있습니다. 이러한 발전은 환자의 예후를 개선하고, 치료 부담을 줄이며, 출혈성 질환 환자의 전반적인 삶의 질을 향상시키는 것을 목표로 합니다. 미국 질병예방통제센터(CDC)에 따르면 2024년 5월 현재 미국에는 약 3만 3,000명의 남성이 혈우병 환자로 추정되고 있습니다.

또한, 의료기술과 연구의 발전으로 효능과 안전성이 개선된 새로운 응고제제가 개발되고 있습니다. 유전자 재조합 응고인자 제제나 반감기 연장 제제와 같은 혁신적인 제제는 환자들에게 더 편리한 치료 옵션을 제공하고 더 나은 치료 결과를 가져옵니다. 2024년 4월, 애브비는 미국에서 FDA 승인을 받은 데스모프레신 아세테이트 주사제를 출시하여 DDAVP 주사제의 제네릭 대체품으로 자리잡았습니다. 역할을 수행했습니다. 이 약은 중추성 당뇨병, 혈우병 A, i형 폰 빌레브란트병 치료를 목적으로 합니다.

또한, 의료 인프라 개선과 예방 의료를 촉진하기 위한 각국 정부의 적극적인 노력과 정책도 업계 성장에 힘을 보태고 있습니다. 각국 정부는 응고인자 결핍증 및 응고 과다증과 같은 질병을 조기에 발견하고 관리할 수 있는 진단 검사 시설을 포함한 양질의 의료 서비스에 대한 접근성을 강화하는 데 주력하고 있습니다. 지혈 및 혈전증에 초점을 맞춘 R&D 활동에 대한 인센티브도 업계가 첨단 기술 개발에 투자하도록 장려하고 있습니다. 예를 들어, 미국 질병예방통제센터(CDC)와 공동으로 진행하는 National Hemophilia Program과 같은 이니셔티브는 지혈 관련 치료법을 발전시키기 위한 연구 노력을 지원하고 있습니다.

규제 요건은 의료 산업을 이끄는 데 있어 중요한 역할을 하고 있습니다. 환자의 안전과 의료의 질에 대한 관심이 높아지면서 미국 식품의약국(FDA), 유럽의약품청(EMA) 등 여러 규제 기관에서 의료 분야에 대한 엄격한 가이드라인을 시행하고 있습니다. 이러한 규제는 제품의 안전성, 유효성 및 품질을 보장하고, 그 결과 이러한 제품에 대한 수요를 촉진하고 있습니다. 예를 들어, FDA는 제품이 동일성, 강도, 품질 및 순도를 유지하기 위해 통제된 조건에서 제조되도록 보장하기 위해 현행 우수의약품 제조 및 품질관리기준(CGMP) 규제를 시행하고 있습니다. 이러한 규제를 준수하기 위해 제조업체는 첨단 기술과 장비에 투자해야 하며, 이는 수요를 견인하고 있습니다.

응고제 세계 시장 보고서 분류

이 보고서는 2018년부터 2030년까지 전 세계, 지역 및 국가별 매출 성장을 예측하고 각 하위 부문의 최신 산업 동향에 대한 분석을 제공합니다. 이 조사에서 Grand View Research, Inc.는 세계 응고제 시장 보고서를 제품, 용도, 투여 경로 및 지역에 따라 세분화했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 응고제 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 응고제 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석
  • 파이프라인 분석

제4장 응고제 시장 : 제품, 추정·동향 분석

• 세계의 응고제 시장 : 제품 대시보드
• 세계의 응고제 시장 : 제품 변동 분석
• 제품별, 매출
• 국소 응고제
• 전신 응고제
• 지혈제

제5장 응고제 시장 : 용도, 추정·동향 분석

• 세계의 응고제 시장 : 용도 대시보드
• 세계의 응고제 시장 : 용도 변동 분석
• 용도별, 매출
• 수술
• 외상 사례
• 혈우병
• 출혈성 질환
• 기타

제6장 응고제 시장 : 투여 채널, 추정·동향 분석

• 세계의 응고제 시장 : 투여 채널 대시보드
• 세계의 응고제 시장 : 투여 채널 변동 분석
• 투여 채널별, 매출
• 국소 투여
• 비경구 투여
• 경구 투여

제7장 응고제 시장 : 제품, 용도, 투여 경로별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 기업/경쟁 분류
• 벤더 구도
  • 주요 기업의 시장 점유율 분석, 2023년
  • Johnson &Johnson.
  • Baxter International Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • Bayer AG
  • Novo Nordisk A/S.
  • CSL Behring
  • Octapharma AG
  • Grifols SA
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited

LSH

영문 목차

영문목차

Coagulants Market Size & Trends

The global coagulants market size was estimated at USD 10.47 billion in 2023 and is projected to grow at a CAGR of 7.2% from 2024 to 2030. The market in healthcare is primarily driven by the increasing prevalence of bleeding disorders and chronic diseases that require blood clotting factors for treatment. Conditions like hemophilia, von Willebrand disease, and thrombophilia necessitate the use of coagulants to manage and control them effectively. The rising incidence of these disorders globally is propelling the demand for this market.

Moreover, technological advancements and the development of novel coagulation therapies are driving innovation and expanding the sector. Manufacturers are investing in research and development to introduce more efficacious and safer products, including recombinant clotting factors and extended half-life products. These advancements aim to enhance patient outcomes, reduce treatment burden, and improve overall quality of life for individuals with bleeding disorders. According to Centers for Disease Control and Prevention, it's estimated that around 33,000 males in the U.S. are living with hemophilia as of May 2024.

Moreover, advancements in medical technology and research have led to development of novel coagulant products with improved efficacy and safety profiles. Innovations like recombinant clotting factors and extended half-life products offer patients more convenient treatment options and better outcomes. These technological advancements drive growth by expanding the range of available therapies and enhancing patient adherence to treatment regimens. In April 2024, Avenacy launched its FDA-approved Desmopressin Acetate Injection in the U.S., serving as a generic alternative to DDAVP Injection. This medication is aimed at treating central diabetes insipidus, hemophilia A, and Type I von Willebrand's disease.

Furthermore, favorable government initiatives and policies aimed at improving healthcare infrastructure and promoting preventive care are boosting the industry. Governments worldwide are focusing on enhancing access to quality healthcare services, including diagnostic testing facilities for early detection and management of disorders such as clotting factor deficiencies and hypercoagulable states. Incentives for research and development activities focused on hemostasis and thrombosis have also encouraged industry players to invest in developing cutting-edge technologies. For instance, initiatives like the National Hemophilia Program are done in collaboration with Centers for Disease Control and Prevention in the U.S. support research efforts to advance hemostasis-related treatments.

Regulatory requirements play a significant role in driving the healthcare industry. With the increasing emphasis on patient safety and quality care, several regulatory bodies including Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented strict guidelines in healthcare settings. These regulations ensure that the products are safe, effective, and of high quality, thereby driving demand for these products. For instance, the FDA has established the Current Good Manufacturing Practice (CGMP) regulations to ensure that they are product under controlled conditions to maintain their identity, strength, quality, and purity. Compliance with these regulations requires manufacturers to invest in advanced technologies and equipment, which in turn drives the demand.

Global Coagulants Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global coagulants market report based on product, application, route of administration, and region.

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Topical Coagulants
• Absorbable Gelatin
• Oxidized Cellulose
• Microfibrillar Collagen
• Other topical coagulants
• Systemic Coagulants
• Vitamin K
• Protamine
• Desmopressin
• Fibrinogen
• Other systemic coagulants
• Hemostatics
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Surgeries
• Trauma Cases
• Hemophilia
• Bleeding Disorders
• Other Applications
• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
• Topical Administration
• Parenteral Administration
• Oral Administration
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

• Latin America

Brazil

Argentina

• Middle East and Africa (MEA)

South Africa

Saudi Arabia

Kuwait

UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Route of Administration
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and Application outlook
  • 2.2.2. Route of Administration outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Coagulants Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements in diagnostic tools and treatment options
    • 3.2.1.2. Increasing prevalence of coagulants disorders and chronic diseases
    • 3.2.1.3. Expanding applications of coagulants testing in various medical fields including hematology, oncology, and critical care
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory Challenges
• 3.3. Coagulants Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Coagulants Market: Product Estimates & Trend Analysis

• 4.1. Global Coagulants Market: Product Dashboard
• 4.2. Global Coagulants Market: Product Movement Analysis
• 4.3. Global Coagulants Market by Product, Revenue
• 4.4. Topical Coagulants
  • 4.4.1. Topical coagulants market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.4.2. Absorbable Gelatin
    • 4.4.2.1. Absorbable gelatin market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.4.3. Oxidized Cellulose
    • 4.4.3.1. Oxidized cellulose market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.4.4. Microfibrillar Collagen
    • 4.4.4.1. Microfibrillar collagen market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.4.5. Other topical coagulants
    • 4.4.5.1. Other topical coagulants market estimates and forecasts 2018 to 2030, (USD Million)
• 4.5. Systemic Coagulants
  • 4.5.1. Systemic coagulants market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.5.2. Vitamin K
    • 4.5.2.1. Vitamin K market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.5.3. Protamine
    • 4.5.3.1. Protamine market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.5.4. Desmopressin
    • 4.5.4.1. Desmopressin market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.5.5. Fibrinogen
    • 4.5.5.1. Fibrinogen market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.5.6. Other systemic coagulants
    • 4.5.6.1. Other systemic coagulants market estimates and forecasts 2018 to 2030, (USD Million)
• 4.6. Hemostatics
  • 4.6.1. Hemostatics coagulants market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 5. Coagulants Market: Application Estimates & Trend Analysis

• 5.1. Global Coagulants Market: Application Dashboard
• 5.2. Global Coagulants Market: Application Movement Analysis
• 5.3. Global Coagulants Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 5.4. Surgeries
  • 5.4.1. Surgeries market estimates and forecasts 2018 to 2030, (USD Million)
• 5.5. Trauma Cases
  • 5.5.1. Trauma cases market estimates and forecasts 2018 to 2030, (USD Million)
• 5.6. Hemophilia
  • 5.6.1. Hemophilia market estimates and forecasts 2018 to 2030, (USD Million)
• 5.7. Bleeding Disorders
  • 5.7.1. Bleeding disorders market estimates and forecasts 2018 to 2030, (USD Million)
• 5.8. Other Applications
  • 5.8.1. Other applications market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 6. Coagulants Market: Route of Administration Estimates & Trend Analysis

• 6.1. Global Coagulants Market: Route of Administration Dashboard
• 6.2. Global Coagulants Market: Route of Administration Movement Analysis
• 6.3. Global Coagulants Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
• 6.4. Topical Administration
  • 6.4.1. Topical administration market estimates and forecasts 2018 to 2030, (USD Million)
• 6.5. Parenteral Administration
  • 6.5.1. Parenteral administration market estimates and forecasts 2018 to 2030, (USD Million)
• 6.6. Oral Administration
  • 6.6.1. Oral Administration market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Coagulants Market: Regional Estimates & Trend Analysis by Product, Application, and Route of Administration

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Vendor Landscape
  • 8.2.1. List of key distributors and channel partners
  • 8.2.2. Key customers
  • 8.2.3. Key company market share analysis, 2023
  • 8.2.4. Johnson & Johnson.
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Baxter International Inc.
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Pfizer Inc.
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Bristol-Myers Squibb Company
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Sanofi S.A.
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Bayer AG
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Novo Nordisk A/S.
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. CSL Behring
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Product benchmarking
    • 8.2.11.4. Strategic initiatives
  • 8.2.12. Octapharma AG
    • 8.2.12.1. Company overview
    • 8.2.12.2. Financial performance
    • 8.2.12.3. Product benchmarking
    • 8.2.12.4. Strategic initiatives
  • 8.2.13. Grifols S.A.
    • 8.2.13.1. Company overview
    • 8.2.13.2. Financial performance
    • 8.2.13.3. Product benchmarking
    • 8.2.13.4. Strategic initiatives
  • 8.2.14. Amgen Inc.
    • 8.2.14.1. Company overview
    • 8.2.14.2. Financial performance
    • 8.2.14.3. Product benchmarking
    • 8.2.14.4. Strategic initiatives
  • 8.2.15. Takeda Pharmaceutical Company Limited
    • 8.2.15.1. Company overview
    • 8.2.15.2. Financial performance
    • 8.2.15.3. Product benchmarking
    • 8.2.15.4. Strategic initiatives

관련자료